Shots:
- Samsung Bioepis has reported the launch of Ustekinumab BS 45 mg Syringe for SC Injection 「NIPRO」, a biosimilar version of Stelara, in Japan, marking the company’s first commercialized product in the country
- The biosimilar will be commercialized by NIPRO CORPORATION under a strategic partnership between Samsung Bioepis & NIPRO in 2025, focused on developing & commercializing multiple biosimilars in Japan, incl. ustekinumab
- Japan’s PMDA granted marketing authorization for the therapy in Dec 2025 for plaque psoriasis and psoriatic arthritis, with the biosimilar added to Japan’s NHI Drug Price Standard following an Official Gazette announcement on May 19, 2026
Ref: Businesswire | Image: Samsung Bioepis & NIPRO | Press Release
Related News: Samsung Bioepis Partners with Sandoz for Up to Five Biosimilar Candidates
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
